Ketamine Hydrochloride Inresa

Ketamine Hydrochloride, the active ingredient in Ketamine Hydrochloride Inresa, is a dissociative anesthetic presented as a sterile injectable solution for intramuscular and intravenous use. It provides rapid induction of anesthesia and analgesia for surgical and procedural settings in adult patients.

GNH USA supplies Ketamine Hydrochloride Inresa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and surgical centres worldwide. The company adheres to stringent quality standards and offers reliable global logistics for qualified healthcare institutions.

Ketamine Hydrochloride is used in anesthesia and pain management by acting as an NMDA receptor antagonist.

- General anesthesia: induces a reversible dissociative state allowing surgical procedures without patient awareness. - Procedural sedation: provides deep sedation for diagnostic or minor therapeutic procedures. - Analgesia: offers potent pain relief for acute severe pain when other agents are insufficient.

Ketamine Hydrochloride may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Hypertension or tachycardia: transient increase in blood pressure and heart rate. - Nausea or vomiting: gastrointestinal discomfort during or after administration. - Dissociation or vivid dreams: sense of detachment from environment. - Salivation or airway secretions: increased oral secretions. - Dizziness or headache: mild neurologic symptoms.

Serious or Rare Side Effects: - Respiratory depression: severe reduction in breathing requiring support. - Psychotomimetic reactions: emergence phenomena such as hallucinations or agitation. - Cardiac arrhythmias: irregular heart rhythms in susceptible patients. - Allergic reactions: anaphylaxis or severe skin rash.

When using Ketamine Hydrochloride, clinicians should observe specific precautions to minimize risks.

- Patient selection: avoid use in patients with uncontrolled hypertension or severe coronary disease. - Psychiatric history: exercise caution in individuals with schizophrenia or psychosis. - Concurrent CNS depressants: monitor for additive respiratory effects. - Pregnancy and lactation: weigh benefits against potential fetal or neonatal risks. - Monitoring: continuously assess cardiovascular and respiratory status during administration. - Store below 25°C: keep in original container, protect from light and moisture.

Ketamine Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Benzodiazepines: may blunt anesthetic effects and increase respiratory depression. - Opioids: synergistic respiratory depression risk. - Sympathomimetic agents: may exacerbate hypertension and tachycardia.

Moderate Interactions (Monitor Closely): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Anticholinergic drugs: may increase secretions and airway obstruction. - CYP450 inhibitors/inducers: may affect ketamine metabolism, requiring dose adjustment.